After 3 years away, BIO marked by first-time handshakes and a drive to survive a bear market’s claws 'Third Rock forever': Firm's latest $1.1B funding round will create 10 new biotechs MorphoSys finds a nice, new billion-dollar home for unwanted assets in oncology pivot Sponsored: An Integrated Approach to Developing Next-Generation Genomic Medicines After ulcerative colitis flop, Immunic regains some momentum with multiple sclerosis update Day One spends day 2 hitting up public markets for $150M in cash Tumor structural genetic signatures offer blueprint for cancer precision medicine Siemens' next-generation SPECT/CT scanner captures FDA clearance The new workout plan: a pill? Researchers find molecule that cuts fat in obese mice after exercise Universal healthcare in U.S. would have saved 212,000 lives, $459B in 2020, study finds Pfizer gives up on Paxlovid in less vulnerable COVID patients after data fail to impress Koneksa teams with Aural Analytics to add speech analysis to digital biomarker offering Featured Story | By Max Bayer In the three years since BIO's last in-person international conference, the biotech market has seesawed from record growth to a cratering bear market. The trend has left many companies scrambling to shore up cash and ink promising partnerships as they look to withstand gusts of fiscal headwinds. read more |
| |
|---|
|
Top Stories By Gabrielle Masson Third Rock Ventures just closed out a massive $1.1 billion fund, bringing its total raised over the last 15 years to an eye-popping $3.8 billion—and the firm told Fierce Biotech is has no plans to slow down. read more By Annalee Armstrong MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology. read more Sponsored by: Danaher Corporation The life sciences companies at Danaher enable gene editing, gene therapy and mRNA medicines with integrated solutions that improve research, development and manufacturing. read more By Nick Paul Taylor Immunic has drummed up some enthusiasm for its multiple sclerosis candidate, highlighting the release of previously published data in a peer-reviewed journal and sharing an update on its next trial to claw back a sliver of the value it lost after its ulcerative colitis flop. read more By Gabrielle Masson Day One Biopharmaceuticals isn’t wasting any time. Just two days after doubling shares on the news that its pediatric brain tumor drug helped patients, the biotech is circling up to raise some cash with an upsized $150 million public offering. read more By Angus Liu In two Nature papers, scientists have profiled the patterns of chromosomal instability in thousands of human tumors and categorized them into what’s known as “copy number signatures,” which could help identify new cancer drug targets. read more By Conor Hale Siemens Healthineers received clearance from the FDA for its latest scanner that combines SPECT and CT imaging into a comparatively smaller package. read more By Gabrielle Masson Mice on treadmills, the effect of exercise potentially placed in a pill—a new study has both. Researchers studied Lac-Phe, a molecule formed in the blood during exercise, and found it can suppress appetite and reduce obesity in certain mice, as published today in Nature. read more By Dave Muoio A hypothetical single-payer system would have saved nearly 339,000 lives from COVID-19 and other diseases during the pandemic's first two years while saving hundreds of billions in spending, researchers estimated in a newly published study. read more By Angus Liu Pfizer’s Paxlovid has proven useful in COVID-19 patients at high risk of severe disease. But the antiviral drug may not help less vulnerable patients, a clinical trial has shown. read more By Gareth Macdonald Novartis and Merck-backed Koneksa Health has partnered with speech-collection and analysis tech firm Aural Analytics to expand its “digital biomarker” offering. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 